Trial Profile
Drug Use Investigation of Ventavis for Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Iloprost (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms JPMS-Ventavis
- Sponsors Bayer
- 23 Oct 2023 Status changed from active, no longer recruiting to completed.
- 19 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 17 Mar 2023 Planned primary completion date changed from 31 Jan 2023 to 31 Mar 2023.